GlassScriptPhysician profile
Sailaja Nootheti
NPI 1356536700
$2,698.25
in general payments reported to CMS, 2019-2025
16 companies · $1,188 in 2025
The $1,188 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2023: $277 · 2024: $879 · 2025: $1,188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,338 · Education: $6.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,337.71 |
| Education | $6.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $941.65 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $351.55 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $302.61 | 2023-2025 | Cuvitru, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $295.67 | 2023-2025 | Dupixent |
| Grifols USA, LLC | $186.62 | 2023-2025 | Xembify, Prolastin-C Liquid |
| Alk-Abello, INC | $152.58 | 2019-2025 | Neffy, Grastek, Ragwitek |
| Pfizer INC. | $100.63 | 2019-2025 | |
| Genzyme Corporation | $77.65 | 2023-2025 | |
| Amgen INC. | $67.04 | 2024-2025 | Tezspire |
| Genentech USA, INC. | $56.53 | 2025 | Xolair |
| Biocryst US Sales Co., LLC | $53.82 | 2024-2025 | Orladeyo |
| Kaleo, INC. | $30.06 | 2023 | Auvi-Q |
| Pharming Healthcare, INC. | $24.71 | 2024 | Ruconest |
| Ars Pharmaceuticals Operations, INC. | $21.08 | 2025 | Neffy |
| Aerin Medical INC. | $19.43 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.62 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sailaja Nootheti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.